OBJECTIVE: To describe travel burden and travel-related financial burden experienced by cancer patients over the first year after diagnosis. DESIGN, SETTING, PARTICIPANTS: Population-based longitudinal cohort of recent adult cancer patients diagnosed with the eight most incident cancers recruited from New South Wales and Victorian Cancer Registries. Self-report survey data were collected at 6 and 12 months after diagnosis from 1410 participants (city: n = 890; regional/remote: n = 520). MAIN OUTCOME MEASURES: Travel time to cancer treatment, living away from home for treatment, travel-related treatment decisions, extent of financial issues, unmet need for financial help. RESULTS: During the first 12 months after diagnosis, outer regional/remote residents had the greatest travel burden; 61% (n = 79) travelled at least 2 hours one way to receive treatment, and 49% (n = 66) lived away from home to receive treatment. Strongest associates of travel burden were living in regional/remote areas (odds ratio (OR) = 18.9-135.7), having received surgery (OR = 6.7) or radiotherapy (OR = 3.6). Between 6 and 12 months after diagnosis, 2% (n = 24) of patients declined cancer treatment because of the time it would take to get to treatment. Patients who travelled more than 2 hours or lived away for treatment reported significantly greater financial difficulties (38%; 40%) than those who did not (12%; 14%), even after adjusting for covariates. CONCLUSIONS: Travel burden is greatest for rural patients, and is associated with greater financial burden. Appropriate and adequate provision of travel and accommodation assistance schemes remains paramount to achieving equitable delivery of cancer services.
OBJECTIVE: To describe travel burden and travel-related financial burden experienced by cancerpatients over the first year after diagnosis. DESIGN, SETTING, PARTICIPANTS: Population-based longitudinal cohort of recent adult cancerpatients diagnosed with the eight most incident cancers recruited from New South Wales and Victorian Cancer Registries. Self-report survey data were collected at 6 and 12 months after diagnosis from 1410 participants (city: n = 890; regional/remote: n = 520). MAIN OUTCOME MEASURES: Travel time to cancer treatment, living away from home for treatment, travel-related treatment decisions, extent of financial issues, unmet need for financial help. RESULTS: During the first 12 months after diagnosis, outer regional/remote residents had the greatest travel burden; 61% (n = 79) travelled at least 2 hours one way to receive treatment, and 49% (n = 66) lived away from home to receive treatment. Strongest associates of travel burden were living in regional/remote areas (odds ratio (OR) = 18.9-135.7), having received surgery (OR = 6.7) or radiotherapy (OR = 3.6). Between 6 and 12 months after diagnosis, 2% (n = 24) of patients declined cancer treatment because of the time it would take to get to treatment. Patients who travelled more than 2 hours or lived away for treatment reported significantly greater financial difficulties (38%; 40%) than those who did not (12%; 14%), even after adjusting for covariates. CONCLUSIONS: Travel burden is greatest for rural patients, and is associated with greater financial burden. Appropriate and adequate provision of travel and accommodation assistance schemes remains paramount to achieving equitable delivery of cancer services.
Authors: Jade C Newton; Claire E Johnson; Harry Hohnen; Max Bulsara; Angela Ives; Sandy McKiernan; Violet Platt; Ruth McConigley; Neli S Slavova-Azmanova; Christobel Saunders Journal: Support Care Cancer Date: 2018-04-27 Impact factor: 3.603
Authors: Jacob E Mandel; Louis Morel-Ovalle; Franz E Boas; Etay Ziv; Hooman Yarmohammadi; Amy Deipolyi; Heeralall R Mohabir; Joseph P Erinjeri Journal: J Digit Imaging Date: 2018-10 Impact factor: 4.056
Authors: Ramez Philips; Daniel Martin; Antoine Eskander; Jeffrey Schord; Nicole Brown; Songzhu Zhao; Guy Brock; Bhavna Kumar; Ricardo Carrau; Enver Ozer; Amit Agrawal; Stephen Y Kang; James W Rocco; David Schuller; Syed Ali; Dukagjin Blakaj; Aashish Bhatt; John Grecula; Theodoros Teknos; Virginia Diavolitsis; Matthew Old Journal: Oral Oncol Date: 2018-01-20 Impact factor: 5.337
Authors: Patricia C Valery; Christina M Bernardes; Vanessa Beesley; Anna L Hawkes; Peter Baade; Gail Garvey Journal: Support Care Cancer Date: 2016-11-10 Impact factor: 3.603
Authors: Adem Sav; Michelle A King; Jennifer A Whitty; Elizabeth Kendall; Sara S McMillan; Fiona Kelly; Beth Hunter; Amanda J Wheeler Journal: Health Expect Date: 2013-01-31 Impact factor: 3.377